Statement by Blue Earth Diagnostics on COVID-19 click here for more information

2021

2020

2019

2018

2017

2016

2015

2014

NEWS FROM 2021

October 19, 2021

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and ¹⁸F-Fluciclovine at Upcoming ASTRO Annual Meeting

September 27, 2021

Blue Earth Diagnostics Announces Results of an Analysis of the Impact of Axumin® (Fluciclovine F 18) PET/CT Imaging on Androgen Deprivation Therapy (ADT) Planning in Recurrent Prostate Cancer

September 15, 2021

Blue Earth Diagnostics Supports Timely Consideration and Passage of the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 by U.S. Congress.

September 8, 2021

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) at Upcoming American Urological Association’s 2021 Annual Meeting

August 10, 2021

Blue Earth Diagnostics Announces Upcoming ¹⁸F-Fluciclovine Presentations at 2021 Society of Neuro-Oncology (SNO) Conference on Brain Metastases

June 8, 2021

Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

June 2, 2021

Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) Presentations at Upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2021

The Lancet Publishes Results of Axumin® (Fluciclovine F 18) PET Imaging Study Demonstrating Improved Patient Outcomes in Patients with Recurrent Prostate Cancer

February 8, 2021

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) at Upcoming 2021 ASCO Genitourinary Cancers Symposium (ASCO GU)

January 12, 2021

Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

January 5, 2021

Blue Earth Diagnostics Acquires Exclusive, Worldwide Rights to Therapeutic Applications of Scintomics’ Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) Technology for Prostate Cancer

NEWS FROM 2020

November 24, 2020

Blue Earth Diagnostics Announces First Patient Doses of PET Imaging Agent rhPSMA-7.3 (18F) in Collaboration with Nucleis Radiopharmaceuticals in Liege, Belgium

October 20, 2020

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and 18F-Fluciclovine at Upcoming ASTRO Annual Meeting

July 21, 2020

Blue Earth Diagnostics Announces Dosing of Initial Patients in Phase 3 SPOTLIGHT Clinical Trial of Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Biochemically Recurrent Prostate Cancer

June 16, 2020

Blue Earth Diagnostics and PETNET Solutions Announce New Commercial Supply Agreement for Axumin® (Fluciclovine F 18) and Investigational rhPSMA-7.3 (18F) Prostate Cancer Imaging Agent

May 18, 2020

Blue Earth Diagnostics Announces Results from Early Clinical Experience with Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Men with Intermediate and High-risk Prostate Cancer

May 1, 2020

Blue Earth Diagnostics CEO Jonathan Allis Appointed Chair of UK Rapid Testing Consortium (UK-RTC) for COVID-19 by UK Department of Health and Social Care

April 21, 2020

Blue Earth Diagnostics continues to expand access to Axumin® (fluciclovine (18F)) with first commercial supply in Slovakia, Europe

March 17, 2020

Blue Earth Diagnostics Announces Dosing of First Patient in Phase 3 LIGHTHOUSE Clinical Trial of Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Newly Diagnosed Prostate Cancer

February 11, 2020

Blue Earth Diagnostics Announces Upcoming Presentations from FALCON Study of Axumin® (Fluciclovine F18) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer

NEWS FROM 2019

September 16, 2019

Results from Blue Earth Diagnostics’ FALCON Trial Show 64% of Patients with Suspected Recurrent Prostate Cancer Had Change in Management Following Axumin® (Fluciclovine F 18) PET/CT Scan

September 10, 2019

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18), 18F-Fluciclovine and 18F-rhPSMA at Upcoming ASTRO Annual Meeting

August 1, 2019

Bracco Imaging announces completion of acquisition of Blue Earth Diagnostics

June 27, 2019

Blue Earth Diagnostics Announces Highlights of Technical University of Munich Presentations on Initial Clinical Experience with 18F-rhPSMA-7 PET Imaging in High Risk Primary and Biochemical Recurrent Prostate Cancer

June 26, 2019

Blue Earth Diagnostics to be Acquired by Global Leader Bracco Imaging

June 26, 2019

Blue Earth Diagnostics Announces Results from Investigational Clinical Study of Safety and Effectiveness of 18F-Fluciclovine PET Imaging in Adult Glioma

June 12, 2019

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18), 18F-Fluciclovine and 18F-rhPSMA at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

May 9, 2019

Blue Earth Diagnostics continues to expand access to Axumin® (fluciclovine (18F)) in Europe

May 6, 2019

Blue Earth Diagnostics Announces Results of Additional Analyses from LOCATE Trial Evaluating Change in Recurrent Prostate Cancer Management Following Axumin® (Fluciclovine F 18) PET/CT Imaging

May 6, 2019

Blue Earth Diagnostics Announces Results from Initial Clinical Experience of 18F-rhPSMA-7 PET Imaging in High-risk Primary and Biochemical Recurrent Prostate Cancer by Technical University of Munich

April 24, 2019

Blue Earth Diagnostics Announces Presentations on Axumin® (Fluciclovine F 18), 18F-Fluciclovine and 18F-rhPSMA at Upcoming American Urological Association’s 2019 Annual Meeting

April 16, 2019

Blue Earth Diagnostics Announces Addition of Axumin® (fluciclovine (18F)) to EAU Guidelines for imaging in patients with biochemical recurrence in Prostate Cancer

March 6, 2019

Blue Earth Diagnostics celebrates five year anniversary

February 12, 2019

First production and administration of Axumin® (fluciclovine (18F)) in Italy.

February 6, 2019

Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) LOCATE Study Presentation at Upcoming ASCO 2019 Genitourinary Cancers Symposium on Impact on Clinical Management of Recurrent Prostate Cancer

NEWS FROM 2018

December 12, 2018

First production and administration of Axumin® (fluciclovine (18F)) in France.

December 10, 2018

Blue Earth Diagnostics Announces U.S. Food and Drug Administration (FDA) Filing Acceptance of Supplemental New Drug Application (sNDA) for 18F-fluciclovine PET Imaging in Glioma

November 19, 2018

Blue Earth Diagnostics Announces Results of Investigational Phase 3 Blinded Image Evaluation Study of 18F-Fluciclovine PET Imaging in Glioma

November 14, 2018

Blue Earth Diagnostics Announces 18F-Fluciclovine Research Presentation at Upcoming Society for Neuro-Oncology (SNO) Annual Scientific Meeting

October 17, 2018

Blue Earth Diagnostics Announces Fluciclovine F 18 Research Presentations at Upcoming ASTRO Annual Meeting

October 12, 2018

Blue Earth Diagnostics wins prestigious “Best Emerging Biotech” award

October 2, 2018

Axumin® (fluciclovine (18F)) receives positive recommendation from Transparency Committee of the French HAS, for use in PET imaging of suspected recurrent prostate cancer

September 11, 2018

The Journal of Urology Publishes Results from Blue Earth Diagnostics’ LOCATE Trial of Role of 18F Fluciclovine PET/CT Imaging in the Management of Men with Recurrent Prostate Cancer

August 9, 2018

Blue Earth Diagnostics shortlisted for prestigious “Best Emerging Biotech Company” award

June 25, 2018

Blue Earth Diagnostics appoints IASON Sp. z o.o. to manufacture and distribute Axumin® (fluciclovine (18F)) in Poland

June 18, 2018

Blue Earth Diagnostics Announces Fluciclovine F 18 Research Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

May 21, 2018

Results from Blue Earth Diagnostics’ LOCATE Trial Show 59% of Patients with Suspected Recurrent Prostate Cancer Had Change in Management Plan Following 18F Fluciclovine PET/CT Scan

May 14, 2018

Blue Earth Diagnostics Announces Presentation on Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer at Upcoming AUA2018, Annual Meeting of the American Urological Association

May 2, 2018

Blue Earth Diagnostics Expands Oncology Portfolio with Exclusive, Worldwide Licensing of Investigational Radiohybrid PSMA-targeted Agents for Prostate Cancer from Scintomics

April 12, 2018

Blue Earth Diagnostics opens new headquarters in Oxford

February 20, 2018

Blue Earth Diagnostics Announces Addition of Axumin® (Fluciclovine F 18) to NCCN Guidelines® for PET Imaging for Suspected Recurrent Prostate Cancer

February 6, 2018

Blue Earth Diagnostics Announces Presentation at Upcoming ASCO 2018 Genitourinary Cancers Symposium on Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer

NEWS FROM 2017

October 10, 2017

Blue Earth Diagnostics and Seibersdorf Laboratories Announce Manufacturing and Distribution Agreements for Axumin® (fluciclovine (18F)) for PET Imaging of Recurrent Prostate Cancer

October 2, 2017

Blue Earth Diagnostics and GE Healthcare sign UK manufacturing agreement

September 6, 2017

Blue Earth Diagnostics Announces Late-Breaking Initial Results of Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer at Upcoming ASTRO Annual Meeting

August 30, 2017

Blue Earth Diagnostics Named as Finalist in First Annual Xconomy Awards

August 11, 2017

Blue Earth Diagnostics shortlisted for “Best Emerging Medtech Company” award

July 27, 2017

Blue Earth Diagnostics appoints M2i to manufacture and distribute Axumin™ in Ireland

June 28, 2017

Blue Earth Diagnostics joins the British Institute of Radiology

May 23, 2017

Blue Earth Diagnostics receives marketing authorisation for Axumin™ (Fluciclovine (18F)) for PET imaging of recurrent prostate cancer

May 22, 2017

Advanced Accelerator Applications and Blue Earth Diagnostics Announce European Manufacturing and Distribution Agreements for Axumin™ (Fluciclovine (18F)) for PET Imaging of Recurrent Prostate Cancer

May 12, 2017

Blue Earth Diagnostics’ FALCON Trial of Fluciclovine (18F) PET/CT Imaging in Recurrent Prostate Cancer Stops Recruitment after Successful Interim Analysis

May 3, 2017

Blue Earth Diagnostics Announces Publication of Reader Training Study Results for AxuminTM (Fluciclovine F 18) PET Imaging of Men with Recurrent Prostate Cancer

March 24, 2017

Blue Earth Diagnostics receives positive CHMP opinion for Axumin™ (Fluciclovine (18F)) for PET imaging of recurrent prostate cancer

February 7, 2017

Blue Earth Diagnostics and Siemens’ PETNET Solutions Increase Patient Access to Axumin™ (Fluciclovine F 18) Injection PET Imaging Agent for Suspected Recurrent Prostate Cancer

NEWS FROM 2016

November 29, 2016

Blue Earth Diagnostics and Northern California PET Imaging Center Announce Region’s First Commercial AxuminTM (Fluciclovine F 18) Administration

October 25, 2016

The Journal of Urology Publishes Blue Earth Diagnostics’ Phase 3 Study Results of AxuminTM (Fluciclovine F 18) for PET Imaging of Recurrent Prostate Cancer

September 8, 2016

Blue Earth Diagnostics Announces First Commercial Administrations of AxuminTM (Fluciclovine F 18) by Atlanta’s Northside Hospital

September 8, 2016

Blue Earth Diagnostics Announces AxuminTM (Fluciclovine F 18) Presentations at Upcoming Scientific Conferences

June 10, 2016

Blue Earth Diagnostics and Siemens’ PETNET Solutions Announce Commercial Availability of AxuminTM (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer

June 9, 2016

Blue Earth Diagnostics Announces AxuminTM (Fluciclovine F 18) Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

June 3, 2016

FDA approves new diagnostic imaging agent to detect recurrent prostate cancer

June 3, 2016

U.S. FDA Approves Blue Earth Diagnostics’ AxuminTM (Fluciclovine F 18) Injection after Priority Review for PET Imaging of Recurrent Prostate Cancer

May 13, 2016

Blue Earth Diagnostics Announces Opening of U.S. Office and Expansion of Management Team

March 31, 2016

Blue Earth Diagnostics begins fluciclovine (18F) studies in Recurrent Prostate Cancer Patients

March 24, 2016

Blue Earth Diagnostics and Norsk medisinsk syklotronsenter AS announce manufacturing and distribution partnership for Fluciclovine (18F)

NEWS FROM 2015

December 2, 2015

Blue Earth Diagnostics and Siemens’ PETNET Solutions announce FDA acceptance of NDA filing for fluciclovine

July 23, 2015

Blue Earth Diagnostics receives £18M Series B Funding from Syncona Partners and establishes Blue Earth Diagnostics Inc

July 8, 2015

Blue Earth Diagnostics granted US and European orphan drug designation for fluciclovine (18F) in the diagnosis of glioma

May 21, 2015

Blue Earth Diagnostics signs an agreement with Siemens’ PETNET Solutions to manufacture and distribute prostate cancer PET imaging agent

NEWS FROM 2014

March 11, 2014

Syncona announces the formation of Blue Earth Diagnostics, a company developing PET agents for the detection of recurrent prostate cancer

2021

European Conferences

2021

U.S. Conferences